These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37332054)

  • 1. Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings.
    Foeldvari I; Torok KS; Anton J; Blakley M; Constantin T; Curran M; Cutolo M; Denton C; Fligelstone K; Ingegnoli F; Li SC; Němcová D; Orteu C; Pilkington C; Smith V; Stevens A; Klotsche J; Khanna D; Costa-Reis P; Del Galdo F; Hinrichs B; Kasapcopur O; Pain C; Ruperto N; Zheng A; Furst DE
    Arthritis Care Res (Hoboken); 2023 Dec; 75(12):2453-2462. PubMed ID: 37332054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
    Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis.
    Zulian F; Woo P; Athreya BH; Laxer RM; Medsger TA; Lehman TJ; Cerinic MM; Martini G; Ravelli A; Russo R; Cuttica R; de Oliveira SK; Denton CP; Cozzi F; Foeldvari I; Ruperto N
    Arthritis Rheum; 2007 Mar; 57(2):203-12. PubMed ID: 17330294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Algorithms for Systemic Sclerosis According to Experts.
    Fernández-Codina A; Walker KM; Pope JE;
    Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features.
    Hoffmann-Vold AM; Distler O; Murray B; Kowal-Bielecka O; Khanna D; Allanore Y;
    RMD Open; 2019; 5(1):e000826. PubMed ID: 30997150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a provisional core set of response measures for clinical trials of systemic sclerosis.
    Khanna D; Lovell DJ; Giannini E; Clements PJ; Merkel PA; Seibold JR; Matucci-Cerinic M; Denton CP; Mayes MD; Steen VD; Varga J; Furst DE;
    Ann Rheum Dis; 2008 May; 67(5):703-9. PubMed ID: 17893248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update of EULAR recommendations for the treatment of systemic sclerosis.
    Kowal-Bielecka O; Fransen J; Avouac J; Becker M; Kulak A; Allanore Y; Distler O; Clements P; Cutolo M; Czirjak L; Damjanov N; Del Galdo F; Denton CP; Distler JHW; Foeldvari I; Figelstone K; Frerix M; Furst DE; Guiducci S; Hunzelmann N; Khanna D; Matucci-Cerinic M; Herrick AL; van den Hoogen F; van Laar JM; Riemekasten G; Silver R; Smith V; Sulli A; Tarner I; Tyndall A; Welling J; Wigley F; Valentini G; Walker UA; Zulian F; Müller-Ladner U;
    Ann Rheum Dis; 2017 Aug; 76(8):1327-1339. PubMed ID: 27941129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
    Khanna D; Distler O; Avouac J; Behrens F; Clements PJ; Denton C; Foeldvari I; Giannini E; Huscher D; Kowal-Bielecka O; Lovell D; Matucci-Cerinic M; Mayes M; Merkel PA; Nash P; Opitz CF; Pittrow D; Rubin L; Seibold JR; Steen V; Strand CV; Tugwell PS; Varga J; Zink A; Furst DE; ;
    J Rheumatol; 2009 Oct; 36(10):2356-61. PubMed ID: 19820225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany].
    Juche A; Siegert E; Mueller-Ladner U; Riemekasten G; Günther C; Kötter I; Henes J; Blank N; Voll RE; Ehrchen J; Schmalzing M; Susok L; Schmeiser T; Sunderkoetter C; Distler J; Worm M; Kreuter A; Horváth ON; Schön MP; Korsten P; Zeidler G; Pfeiffer C; Krieg T; Hunzelmann N; Moinzadeh P
    Z Rheumatol; 2020 Dec; 79(10):1057-1066. PubMed ID: 32040755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Delphi exercise and cluster analysis to aid in the development of potential classification criteria for systemic sclerosis using SSc experts and databases.
    Coulter C; Baron M; Pope JE
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):24-30. PubMed ID: 23557780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma.
    Li SC; Torok KS; Pope E; Dedeoglu F; Hong S; Jacobe HT; Rabinovich CE; Laxer RM; Higgins GC; Ferguson PJ; Lasky A; Baszis K; Becker M; Campillo S; Cartwright V; Cidon M; Inman CJ; Jerath R; O'Neil KM; Vora S; Zeft A; Wallace CA; Ilowite NT; Fuhlbrigge RC;
    Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1175-85. PubMed ID: 22505322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
    Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
    J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.
    Stöcker JK; Schouffoer AA; Spierings J; Schriemer MR; Potjewijd J; de Pundert L; van den Hoogen FHJ; Nijhuis-van der Sanden MWG; Staal JB; Satink T; Vonk MC; van den Ende CHM;
    Rheumatology (Oxford); 2022 Apr; 61(4):1476-1486. PubMed ID: 34260723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of cutaneous vascular complications in systemic scleroderma: experience from the German network.
    Herrgott I; Riemekasten G; Hunzelmann N; Sunderkötter C
    Rheumatol Int; 2008 Aug; 28(10):1023-9. PubMed ID: 18320192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Influencing Patient Decision-Making Concerning Treatment Escalation in Raynaud's Phenomenon Secondary to Systemic Sclerosis.
    Hughes M; Huang S; Pauling JD; Sabbagh M; Khanna D
    Arthritis Care Res (Hoboken); 2021 Dec; 73(12):1845-1852. PubMed ID: 34057304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.